Related Experiment Video
Updated: May 15, 2026
10:20
Simultaneous Assessment of Kinship, Division Number, and Phenotype via Flow Cytometry for Hematopoietic Stem and Progenitor Cells
Published on: March 24, 2023
Transgenerational cell fate profiling: a method for the graphical presentation of complex cell cycle alterations.
Mohamed Jemaà1, Lorenzo Galluzzi, Oliver Kepp
1Institut Gustave Roussy, Villejuif, France.
Cell Cycle (Georgetown, Tex.)
|December 21, 2012
Summary
Tetraploid cells drive cancer and resist treatment. A new method using SP600125 kinase inhibitor preferentially kills these cells by disrupting mitosis, offering a novel approach to cancer therapy.
Area of Science:
- Oncology
- Cell Biology
- Genetics
Background:
- Tetraploid cell generation is a key driver of cancer, leading to aneuploidy and genomic instability.
- Tetraploid cells exhibit increased resistance to radio- and chemotherapy, posing a therapeutic challenge.
Purpose of the Study:
- To develop a strategy for selectively eliminating tetraploid tumor cells.
- To investigate the effects of the kinase inhibitor SP600125 on tetraploid cells.
- To introduce a novel method for analyzing cell fate in heterogeneous populations.
Main Methods:
- Utilized live videomicroscopy to observe cellular responses to SP600125.
- Quantified differential responses between diploid and tetraploid cancer cells.
- Developed a graphical model termed "transgenerational cell fate profiling".
Main Results:
- SP600125 was found to disrupt mitosis and induce apoptosis preferentially in near-tetraploid cancer cells.
- The drug's effects were less pronounced in parental diploid cancer cells.
- The proposed "transgenerational cell fate profiling" model effectively quantifies differential cell responses.
Conclusions:
- The kinase inhibitor SP600125 shows potential for selectively targeting tetraploid tumor cells.
- "Transgenerational cell fate profiling" offers a valuable tool for analyzing cell cycle alterations and cell fate in mixed cell populations.
- This approach may enhance cancer treatment strategies by overcoming therapeutic resistance associated with tetraploidy.
